Correction (DOI:10.1016/j.amjcard.2006.07.017);Controlled-Release Carvedilol in the Treatment of Essential Hypertension

American Journal of Cardiology

Volumn 98, Issue 7 SUPPL., 2006, Pages 32-38

  Weber, Michael A ^a   Sica, Domenic A ^b   Tarka, Elizabeth A ^c   Iyengar, Malini ^c   Fleck, Richard ^c   Bakris, George L ^d  

^a SUNY Downstate Medical Center   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; PLACEBO;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SITTING; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

EID: 33749126575     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.10.012     Document Type: Erratum

References (26)

1. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., and Roccella E.J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
2. Ruffolo R.R., Boyle D.A., Venuti R.P., and Lukas M.A. Preclinical and clinical pharmacology of carvedilol. J Hum Hypertens 7 (1993) S2-S15
3. Nichols A.J., Sulpizio A.C., Ashton D.J., Hieble J.P., and Ruffolo Jr. R.R. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 39 (1989) 327-336
4. Ruffolo R.R., Gellai M., Hieble J.P., Willette R.N., and Nichols A.J. The pharmacology of carvedilol. Eur J Clin Pharmacol 38 (1990) S82-S88
5. Nichols A.J., Gellai M., and Ruffolo Jr. R.R. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol 5 (1991) 25-38
6. Feuerstein G.Z., and Ruffolo Jr. R.R. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 16 (1995) 38-42
7. Sung C.P., Arleth A.J., and Ohlstein E.H. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 21 (1993) 221-227
8. Bakris G.L., Fonseca V., Katholi R.E., McGill J.B., Messerli F.H., Phillips R.A., Raskin P., Wright Jr. J.T., Oakes R., Lukas M.A., Anderson K.M., Bell D.S.H., and GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004) 2227-2236
9. Tenero D.M., Henderson L.S., Baidoo C.A., Harter A.H., Campanile A.M., Danoff T.M., and Boyle D. Pharmacokinetic properties of a new controlled-release formulation of carvedilol. Am J Cardiol 98 suppl (2006) 5L-16L
10. Weber MA, Bakris GL, Tarka EA, Iyengar M, Fleck R, Sica DA. Efficacy of a new once-daily formulation for carvedilol for the treatment of hypertension. J Clin Hypertens 2006, in press.
11. Sesso H.D., Stampfer M.J., Rosner B., Hennekens C.H., Gaziano J.M., Manson J.E., and Glynn R.J. Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men. Hypertension 36 (2000) 801-807
12. Lee M.L., Rosner B.A., and Weiss S.T. Relationship of blood pressure to cardiovascular death: the effects of pulse pressure in the elderly. Ann Epidemiol 9 (1999) 101-107
13. Girerd X., Laurent S., Pannier B., Asmar R., and Safar M. Arterial distensibility and left ventricular hypertrophy in patients with sustained essential hypertension. Am Heart J 122 (1991) 1210-1214
14. Benetos A., Safar M., Rudnichi A., Smulyan H., Richard J.L., Ducimetieere P., and Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 30 (1997) 1410-1415
15. Kannel W.B., Wolf P.A., McGee D.L., Dawber T.R., McNamara P., and Castelli W.P. Systolic blood pressure, arterial rigidity, and risk of stroke: the Framingham study. JAMA 245 (1981) 1225-1229
16. Madhavan S., Ooi W.L., Cohen H., and Alderman M.H. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 23 (1994) 395-401
17. Mitchell G.F., Moye L.A., Braunwald E., Rouleau J.L., Bernstein V., Geltman E.M., Flaker G.C., Pfeffer M.A., and SAVE [Survival and Ventricular Enlargement] investigators. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. Circulation 96 (1997) 4254-4260
18. Kannel W.B., Kannel C., Paffenbarger Jr. R.S., and Cupples L.A. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 113 (1987) 1489-1494
19. Diaz A., Bourassa M.G., Guertin M.C., and Tardif J.C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26 (2005) 967-974
20. Holzgreve H., Nakov R., Beck K., and Janka H.U. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 16 (2003) 381-386
21. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di Lenarda A., Hanrath P., Komajda M., Lubsen J., Lutiger B., Metra M., Remme W.J., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
22. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
23. ALLHAT Officers and Coordinators, for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
24. Bakris G.L., Weir M.R., Shanifar S., Zhang Z., Douglas J., van Dijk D.J., and Brenner B.M. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 163 (2003) 1555-1565
25. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 (2001) 1296-1310
26. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 (2005) 487-497